Revenue from Pfizer#39;s COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts#39; forecast and Pfizer#39;s own lowered view of $12.5 billion for this year.
Revenue from Pfizer#39;s COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts#39; forecast and Pfizer#39;s own lowered view of $12.5 billion for this year. Revenue from Pfizer#39;s COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts#39; forecast and Pfizer#39;s own lowered view of $12.5 billion for this year. Moneycontrol Latest News Read More
English 
हिन्दी